Advertisement


Tomohiro Aoki, MD, PhD, on the Spatial Tumor Microenvironment and Outcome of Relapsed/Refractory Classical Hodgkin Lymphoma

2022 ASH Annual Meeting and Exposition

Advertisement

Tomohiro Aoki, MD, PhD, of the University of British Columbia and the Centre for Lymphoid Cancer at BC Cancer, discusses a novel prognostic model applicable to patients with relapsed or refractory classical Hodgkin lymphoma who were treated with autologous stem cell transplantation. The model has shown the interaction between the biomarker CXCR5 on HRS cells (Hodgkin and Reed/Sternberg cells, hallmarks of Hodgkin lymphoma) with specific follicular T helper cells and macrophages, a prominent crosstalk axis in relapsed disease. This insight opens new avenues to developing predictive biomarkers (Abstract 71).

 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Development of the spatially informed biomarker, that is the main goal of our study. Our study here is focusing on relapsed refractory Hodgkin lymphoma because, as you know, despite the recent treatment advancements, still about 20 to 30% of patients experience relapsed disease, and about half of them eventually succumb to their disease. Importantly, there's no biomarker we can utilize in daily clinical practice setting yet. So, our study goals are describing the tumor microbiome ecosystem for the relapsed/refractory Hodgkin lymphoma and develop some novel prognostic model for relapsed/refractory Hodgkin lymphoma. For these goals, we applied imaging mass cytometry, which enabled us to visualize more than 37 protein marker in the spatial context, and we applied IMC using the unique cohorts, which consist of 73 paired diagnostic and relapsed biopsy of Hodgkin lymphoma. Primary advantage of the imaging mass cytometry data is that we can capture the complex spatial information at single cell resolutions. To capture the complex information, we established the pipeline called spatial score, so that we can utilize the information for the biomarker development. First, we describe the unique contrast between early relapsed biopsy and relapse biopsy. In brief, we identified that early relapsed biopsy, in general, shares micro-environment patterns between diagnostic and relapsed biopsy. In contrast, where relapsed biopsy shows the significant difference between diagnostic and relapsed biopsies. Next, we sought to develop the micro-environments best prognostic model, using the spatial information. So first, using the best model and using amazing math rudimentary data, we identified the four variables which is significantly associated with the outcome in relapsed/refractory Hodgkin lymphoma which includes CXCR5 positive HRS cells, CD4 positive T cells, macrophage and CXCR5 positive B cell population. Using those four variables, we have developed a novel prognostic model called RHL4S, which produced highly significant [inaudible 00:02:50] group in relapsed/refractory Hodgkin lymphoma, in harmony, treated with high dose chemotherapy, followed by stem cell transplantation. We further identified the unique micro-environment patterns of the six certified positive HRS cells, which are spatially arranged together and form cell clusters. Their unique interactions with the six certified positive initial population, including macrophage and T cells. In summary, we have developed a novel prognostic model in relapsed/refractory Hodgkin lymphoma and importantly, we have now opened up a new avenue of spatially informed biomarker. I believe that this new concept can be applicable to any of the cancer types, not limited to Hodgkin lymphoma. Now, we are verifying our findings and our ultimate goal is we can utilize those spatially informed biomarker in the daily clinical practice setting. Now we are translating our IMC data findings into the managed IT settings so that we can utilize the information into the daily clinical practice.

Related Videos

Leukemia

Andrew Matthews, MD, on AML: Real-World Effectiveness of 7 + 3 Intensive Chemotherapy vs Venetoclax and a Hypomethylating Agent

Andrew Matthews, MD, of the Abramson Cancer Center, University of Pennsylvania, discusses findings from a large, multicenter study that showed superior outcomes with 7 + 3 chemotherapy (cytarabine continuously for 7 days, along with short infusions of an anthracycline on each of the first 3 days) vs venetoclax in patients with acute myeloid leukemia (AML). In this real-world data set, the 7 + 3 cohort outperformed historical benchmarks in overall survival and early mortality, perhaps reflecting improved later lines of therapy and patient selection. Prospective studies (such as NCT04801797) must confirm the superiority of intensive chemotherapy (Abstract 426).

 

Multiple Myeloma
Immunotherapy

Eileen M. Boyle, MD, PhD, on Multiple Myeloma: Sustained MRD Negativity in Newly Diagnosed Disease Treated with Immunotherapy Regimens

Eileen M. Boyle, MD, PhD, of the Perlmutter Cancer Center, NYU Langone Health, discusses Fc-mediated antibody effector function, inflammation resolution, and oligoclonality and their role in predicting sustained measurable residual disease negativity in patients with newly diagnosed multiple myeloma who were treated with immunotherapy regimens. For the first time, an analysis of T-cell receptors shows that oligoclonal profiles seen on treatment may influence the fitness of the immune response (Abstract 100).

Multiple Myeloma

Paul G. Richardson, MD, on Multiple Myeloma: Mezigdomide Plus Dexamethasone in Relapsed and Refractory Disease

Paul G. Richardson, MD, of the Dana-Farber Cancer Institute, discusses preliminary results from the dose-expansion phase of the CC-92480-MM-001 Trial, which showed promising efficacy in patients with relapsed and refractory multiple myeloma, including those with prior BCMA-targeted therapies. Patients in these two groups had an overall response rate of 40% and 50%, respectively. The results support the development of mezigdomide, currently being evaluated in combination with standard therapies in multiple myeloma as part of a large, ongoing phase I/II trial (NCT03989414) and planned phase III studies (Abstract 568).

Lymphoma
Immunotherapy

Tycel J. Phillips, MD, on Mantle Cell Lymphoma: New Findings on Glofitamab Monotherapy

Tycel J. Phillips, MD, of the City of Hope National Medical Center, discusses data that showed fixed-duration glofitamab monotherapy induced high and durable complete response rates in patients with mantle cell lymphoma (MCL) who received obinutuzumab pretreatment. This is one of the largest data sets and longest follow-ups reported with a CD20/CD3 bispecific monoclonal antibody for patients with relapsed or refractory MCL (Abstract 74).

Leukemia
Genomics/Genetics

Irene Roberts, MD, on Leukemogenesis in Infants With Trisomy 21

Irene Roberts, MD, of Oxford’s Weatherall Institute of Molecular Medicine, discusses children with Down syndrome, who have a more than 100-fold increased risk of developing acute myeloid leukemia before their fourth birthday compared to children without Down syndrome. Their risk of acute lymphoblastic leukemia is also increased by around 30-fold. Dr. Roberts details current knowledge about the biologic and molecular basis of this relationship between leukemia and Down syndrome, the role of trisomy 21 in leukemogenesis, and the clinical implications of these findings.

Advertisement

Advertisement




Advertisement